公开(公告)号：US10273474B2

公开(公告)日：2019-04-30

申请号：US14387853

申请日：2013-03-14

申请人： WASHINGTON UNIVERSITY ,  ISIS PHARMACEUTICALS, INC.

发明人： Timothy M. Miller ,  Sarah Devos ,  C. Frank Bennett ,  Frank Rigo

IPC分类号： C12N15/113 ,  C07H21/02 ,  C07H21/04

摘要： Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

公开(公告)号：US20200032257A1

公开(公告)日：2020-01-30

申请号：US16298607

申请日：2019-03-11

申请人： WASHINGTON UNIVERSITY ,  ISIS PHARMACEUTICALS, INC.

发明人： Timothy M. Miller ,  Sarah Devos ,  C. Frank Bennett ,  Frank Rigo

IPC分类号： C12N15/113 ,  C07H21/02 ,  C07H21/04

摘要： Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

公开(公告)号：US20150275205A1

公开(公告)日：2015-10-01

申请号：US14387853

申请日：2013-03-14

申请人： WASHINGTON UNIVERSITY ,  ISIS PHARMACEUTICALS, INC.

发明人： Timothy M. Miller ,  Sarah Devos ,  C. Frank Bennett ,  Frank Rigo

IPC分类号： C12N15/113

CPC分类号： C12N15/113 ,  C07H21/02 ,  C07H21/04 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/3525

摘要： Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.

摘要翻译： 本文公开了用Tau反义化合物减少动物中Tau mRNA和蛋白质的表达的方法。 还公开了用Tau反义化合物调节动物中Tau mRNA的剪接的方法。 这样的方法可用于治疗，预防或改善有需要的个体中的神经变性疾病。 可以用施用Tau反义寡核苷酸治疗，预防和改善的神经变性疾病的实例包括阿尔茨海默氏病，颞痴呆（FTD），FTDP-17，进行性核核麻痹，慢性创伤性脑病，癫痫和德拉维特综合征。

公开(公告)号：US11781135B2

公开(公告)日：2023-10-10

申请号：US16298607

申请日：2019-03-11

申请人： Washington University ,  Biogen MA Inc.

发明人： Timothy M. Miller ,  Sarah Devos ,  C. Frank Bennett ,  Frank Rigo

IPC分类号： C12N15/113 ,  C07H21/02 ,  C07H21/04

CPC分类号： C12N15/113 ,  C07H21/02 ,  C07H21/04 ,  C12N2310/11 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/3341 ,  C12N2310/341 ,  C12N2310/346 ,  C12N2310/321 ,  C12N2310/3525

摘要： Disclosed herein are methods for reducing expression of Tau mRNA and protein in an animal with Tau antisense compounds. Also disclosed are methods for modulating splicing of Tau mRNA in an animal with Tau antisense compounds. Such methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof. Examples of neurodegenerative diseases that can be treated, prevented, and ameliorated with the administration Tau antisense oligonucleotides include Alzheimer's Disease, Fronto-temporal Dementia (FTD), FTDP-17, Progressive Supranuclear Palsy, Chronic Traumatic Encephalopathy, Epilepsy, and Dravet's Syndrome.